Related references
Note: Only part of the references are listed.The Cystine/Glutamate Antiporter System xc- in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities
Jan Lewerenz et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Concurrent regulation of the transcription factors Nrf2 and ATF4 mediates the enhancement of glutathione levels by the flavonoid fisetin
Jennifer L. Ehren et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Glutathione synthesis
Shelly C. Lu
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Increased xCT Expression Correlates With Tumor Invasion and Outcome in Patients With Glioblastomas
Satoru Takeuchi et al.
NEUROSURGERY (2013)
Nrf2 activation is associated with Z-DNA formation in the human HO-1 promoter
Atsushi Maruyama et al.
NUCLEIC ACIDS RESEARCH (2013)
Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma
Hiroki Kinoshita et al.
ONCOLOGY REPORTS (2013)
Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells
Wei Qi et al.
PLOS ONE (2013)
The resistance mechanisms of proteasome inhibitor bortezomib
Shuqing Lu et al.
BIOMARKER RESEARCH (2013)
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma
David S. Siegel
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Implication of Nrf2 and ATF4 in differential induction of CHOP by proteasome inhibition in thyroid cancer cells
Zhi-Hong Zong et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
Deborah J. Kuhn et al.
BLOOD (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Activating transcription factor 4 increases chemotherapeutics resistance of human hepatocellular carcinoma
Zhuhong Zhang et al.
CANCER BIOLOGY & THERAPY (2012)
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Yoichiro Mitsuishi et al.
CANCER CELL (2012)
Mutation of ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression
J. Lewerenz et al.
CELL DEATH AND DIFFERENTIATION (2012)
Targeting the ATF4 pathway in cancer therapy
Dean C. Singleton et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
The Keap 1-Nrf2 system in cancers: stress response and anabolic metabolism
Yoichiro Mitsuishi et al.
FRONTIERS IN ONCOLOGY (2012)
The Cystine/Cysteine Cycle and GSH Are Independent and Crucial Antioxidant Systems in Malignant Melanoma Cells and Represent Druggable Targets
Roberta Vene et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc- and Thereby Promotes Tumor Growth
Takatsugu Ishimoto et al.
CANCER CELL (2011)
Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma
Weijie Guo et al.
CANCER LETTERS (2011)
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Keiko Taguchi et al.
GENES TO CELLS (2011)
Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview
Ken Itoh et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types
Xiang Ling et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Novel Targeted Agents for the Treatment of Bladder Cancer: Translating Laboratory Advances into Clinical Application
Xiaoping Yang et al.
INTERNATIONAL BRAZ J UROL (2010)
Bortezomib A Review of its Use in Patients with Multiple Myeloma
Monique P. Curran et al.
DRUGS (2009)
Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathway
R-S Chen et al.
ONCOGENE (2009)
ATF4-dependent transcription mediates signaling of amino acid limitation
Michael S. Kilberg et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2009)
The present and future burden of urinary bladder cancer in the world
Martine Ploeg et al.
WORLD JOURNAL OF UROLOGY (2009)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Proteasome inhibitors in cancer therapy: Lessons from the first decade
Robert Z. Orlowski et al.
CLINICAL CANCER RESEARCH (2008)
Activating transcription factor 4
Kurosh Ameri et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
The xc- cystine/glutamate antiporter:: A potential target for therapy of cancer and other diseases
Maisie Lo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
The cystine/cysteine cycle:: a redox cycle regulating susceptibility versus resistance to cell death
A. Banjac et al.
ONCOGENE (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Sulfasalazine-induced cystine starvation: Potential use for prostate cancer therapy
Daniel W. Doxsee et al.
PROSTATE (2007)
Combination therapy with IFN-α plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells
Angela Papageorgiou et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Expression of the cystine-glutamate exchanger (xc-) in retinal ganglion cells and regulation by nitric oxide and oxidative stress
Y Dun et al.
CELL AND TISSUE RESEARCH (2006)
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
J Codony-Servat et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation
P Nioi et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance
Y Huang et al.
CANCER RESEARCH (2005)
Inhibition of cystine uptake disrupts the growth of primary brain tumors
WJ Chung et al.
JOURNAL OF NEUROSCIENCE (2005)
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells
LM Lashinger et al.
CANCER RESEARCH (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Glutathione metabolism and its implications for health
GY Wu et al.
JOURNAL OF NUTRITION (2004)
Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation
H Sato et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Membrane topology of system xc- light subunit reveals a re-entrant loop with substrate-restricted accessibility
E Gasol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Therapeutic approaches to bladder cancer: identifying targets and mechanisms
RJ Cote et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2003)
The proteasome: structure, function, and role in the cell
J Adams
CANCER TREATMENT REVIEWS (2003)
Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines
S Okuno et al.
BRITISH JOURNAL OF CANCER (2003)
Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression
H Sasaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc- cystine transporter:: a new action for an old drug
PW Gout et al.
LEUKEMIA (2001)
Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein - Implication for heme oxygenase-1 gene regulation
CH He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
